Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection

• Status: Terminated
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Treatment of acute primary HIV infection may improve long-term outcome. However, optimal treatment is still debated. The ANRS 112-INTERPRIM trial evaluates three different therapeutical strategies, combining permanent or intermittent HAART and a cytokine, interferon alpha, in order to determine which combination allows the best control of HIV viremia after 24 weeks of antiretroviral treatment interruption

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
• Collaborator: Hoffmann-La Roche
• Treatments: Anti-Retroviral Agents; Interferon-alpha; Interferons

Criteria

Inclusion Criteria:

• P24 antigen with positive neutralization or positive plasma HIV RNA

• Negative or not complete Western Blot

• With symptoms or not

• Written informed consent

Exclusion Criteria:

• Previous antiretroviral treatment

• Pregnancy

• Biological abnormalities

• Hepatitis C or B